Research
Hormonal
PPARg is the master regulator of adipocyte differentiation; its deletion prevents fat cell development, while its activation is sufficient to induce adipogenesis in non-adipocyte cell types.
PPARg is the genetic switch for fat cell creation. Drugs like thiazolidinediones target this receptor to treat diabetes, highlighting its central role in metabolic health and fat storage.
GoodSupportsHIGH confidence
PPARg is a member of a superfamily of hormone nuclear receptors and has been shown to be crucial and sufficient for adipocyte development in vitro and in vivo... PPARg deletion in mice results in placental dysfunction and embryonic lethality... mice with adipose tissue–specific loss of PPARg display decreased fat pad size and insulin resistance in adipose tissue and liver.
Why this rating
Strong evidence from multiple knockout and transgenic mouse models.
Source
Adipogenesis
K. Sarjeant et al. · Cold Spring Harbor Perspectives in Biology · 2012
DOI 10.1101/cshperspect.a008417
narrative_reviewCited 321×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Brown adipose tissue (BAT) and beige/brite adipocytes within white adipose tissue (WAT) are metabolically active depots that can correct WAT pathologies and improve whole-body insulin sensitivity through thermogenesis mediated by UCP1.Moderate
- Beige/brite adipocytes, found interspersed in white adipose tissue, can be recruited and transformed into a brown fat-like phenotype through mechanisms involving PRDM16, beta-3-adrenergic stimulation, and cold exposure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →